Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Other(1)

Detailed Status

unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

unknown150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
unknownphase_3

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

NCT01532856
completedphase_3

Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.

NCT01070862

Clinical Trials (2)

Showing 2 of 2 trials
NCT01532856Phase 3

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

Unknown
NCT01070862Phase 3

Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2